Baptist Health South Florida
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Baptist Health South Florida sits in the top decile of US sponsors by registered trial count (#434 of 15,742 sponsors by registered trial count).
Baptist Health South Florida: 40 sponsored US clinical trials, 17 recruiting.
Baptist Health South Florida sponsors 40 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain Cancer, with 5 trials.
Top-decile sponsor footprint
Baptist Health South Florida ranks in the top decile of sponsors by registered trial count (#434 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
40 total, page 1 of 1
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
NCT07455903
MucoLock™ for Treatment of Stomatitis
NCT07506018
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
NCT06991101
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
NCT06397560
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
NCT05756985
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
NCT05681195
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
NCT06048094
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT05789589
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT05679674
ZYNRELEF for Pain Management in Total Knee Arthroplasty
NCT05644496
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
NCT05554302
Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease
NCT05534321
Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05425004
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
NCT04689048
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
NCT05504681
Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column
NCT04802603
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
NCT01524211
Ablative Stereotactic MR-Guided Adaptive Reirradiation
NCT06397573
Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation
NCT04375891
Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors.
NCT03972514
The Miami Heart Study at Baptist Health South Florida
NCT02508454
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
NCT07454668
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT05553522
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
NCT04939246
Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)
NCT04762771
Pembrolizumab and Olaparib in Cervical Cancer Patients
NCT04483544
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
NCT04376502
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
NCT03430791
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
NCT03490760
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
NCT03274661
Repeated TMS at Low Frequencies to Reduce Seizure Occurrence
NCT03154307
Acute Chest Pain Imaging in the ED With the Combine CCTA and CT Perfusion
NCT02538861
South Miami Hospital Fibroid Registry
NCT02362009
The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis
NCT02082717
A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer
NCT02037542
A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome
NCT01912209
Electroencephalogram (EEG) Triggered Functional Magnetic Resonance Imaging (fMRI) in Epilepsy Patients
NCT02193932
Radioprotective Light-weight Caps in the Interventional Cardiology Setting
NCT01620658
New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)
NCT01450969
New Fabric Attenuation Device in Endovascular Interventional Radiology II (PREFER II)
NCT01611454
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 9 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Baptist Health South Florida pipeline
17 recruiting of 40 indexed (43% open); 9 completed (23%).
Phase mix: 2 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Brain Cancer (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baptist Health South Florida: open-pipeline peers nationwide
Peers matched on 40 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Baptist Health South Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 40 trials (± recruiting share)
- BTL Industries · 40 trials · 8% recruiting
- Celgene Corporation · 40 trials · 0% recruiting
- Harvard School of Public Health (HSPH) · 40 trials · 3% recruiting
- Intuitive Surgical · 40 trials · 8% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Baptist Health South Florida page
40 registered trials is a research-attention snapshot, not an endorsement of Baptist Health South Florida or any single study.
- 17 of Baptist Health South Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Brain Cancer is the condition Baptist Health South Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Baptist Health South Florida pipeline card: 40 registered trials from official public datasets.Report a data error.